SOURCE: The Bedford Report

The Bedford Report

June 22, 2011 08:16 ET

Marina Biotech and Sequenom Find Themselves in Enviable Positions

The Bedford Report Provides Stock Research on Marina Biotech and Sequenom

NEW YORK, NY--(Marketwire - Jun 22, 2011) - The biotech industry is generating significant investor interest this year as an influx of new and lucrative therapies work their way towards regulatory approval. Although younger, unprofitable firms are having difficulty securing funding, reports suggest biotech companies with promising pipelines should be able to secure necessary capital. The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on Marina Biotech, Inc. (NASDAQ: MRNA) and Sequenom, Inc. (NASDAQ: SQNM). Access to the full company reports can be found at:

www.bedfordreport.com/MRNA

www.bedfordreport.com/SQNM

According to a recent report from Ernst & Young, US biotech companies raised $25 billion last year -- a 15 percent jump over the previous year and the highest amount since 2007. Of concern is that more than 82 percent of that funding went to 20 percent of the companies. Younger, unprofitable companies in the US that depend on funding from venture capital firms, stock sales and partnerships saw available capital decline 21 percent in 2010.

The Bedford Report releases investment research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Earlier this month Sequenom, Inc. announced that it landed a $30M credit facility from Silicon Valley Bank. The biotech firm said the new funding will go towards development and commercialization of new products, as well as other near term growth initiatives.

Marina Biotech CEO Michael French says that the company is in an "enviable position." French says that others are funding the development and human testing of Marina Biotech's RNA-based therapeutics. For example, Marina Biotech recently entered an exclusive agreement with the Debiopharm Group for the development and commercialization of the bladder cancer program.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.bedfordreport.com/disclaimer.

Contact Information